The role of viral and bacterial infections in the pathogenesis of IPF: a systematic review and meta-analysis.
Bacterial infection
Epidemiology
Idiopathic pulmonary fibrosis
Meta-analysis
Viral infection
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
17
10
2020
accepted:
04
02
2021
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Several risk factors such as smoking, air pollution, inhaled toxins, high body mass index and infectious agents are involved in the pathogenesis of IPF. In the present study, this meta-analysis study investigates the prevalence of viral and bacterial infections in the IPF patients and any possible association between these infections with pathogenesis of IPF. The authors carried out this systematic literature review from different reliable databases such as PubMed, ISI Web of Science, Scopus and Google Scholar to December 2020.Keywords used were the following "Idiopathic pulmonary fibrosis", "Infection", "Bacterial Infection" and "Viral Infection", alone or combined together with the Boolean operators "OR", "AND" and "NOT" in the Title/Abstract/Keywords field. Pooled proportion and its 95% CI were used to assess the prevalence of viral and bacterial infections in the IPF patients. In this systematic review and meta-analyses, 32 studies were selected based on the exclusion/inclusion criteria. Geographical distribution of included studies was: eight studies in American people, 8; in European people, 15 in Asians, and one in Africans. The pooled prevalence for viral and bacterial infections w ere 53.72% (95% CI 38.1-69.1%) and 31.21% (95% CI 19.9-43.7%), respectively. The highest and lowest prevalence of viral infections was HSV (77.7% 95% CI 38.48-99.32%), EBV (72.02%, 95% CI 44.65-90.79%) and Influenza A (7.3%, 95% CI 2.66-42.45%), respectively. Whereas the highest and lowest prevalence in bacterial infections were related to Streptococcus sp. (99.49%, 95% CI 96.44-99.9%) and Raoultella (1.2%, 95% CI 0.2-3.08%), respectively. The results of this review were confirmed that the presence of viral and bacterial infections are the risk factors in the pathogenesis of IPF. In further analyses, which have never been shown in the previous studies, we revealed the geographic variations in the association strengths and emphasized other methodological parameters (e.g., detection method). Also, our study supports the hypothesis that respiratory infection could play a key role in the pathogenesis of IP.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Several risk factors such as smoking, air pollution, inhaled toxins, high body mass index and infectious agents are involved in the pathogenesis of IPF. In the present study, this meta-analysis study investigates the prevalence of viral and bacterial infections in the IPF patients and any possible association between these infections with pathogenesis of IPF.
METHODS
METHODS
The authors carried out this systematic literature review from different reliable databases such as PubMed, ISI Web of Science, Scopus and Google Scholar to December 2020.Keywords used were the following "Idiopathic pulmonary fibrosis", "Infection", "Bacterial Infection" and "Viral Infection", alone or combined together with the Boolean operators "OR", "AND" and "NOT" in the Title/Abstract/Keywords field. Pooled proportion and its 95% CI were used to assess the prevalence of viral and bacterial infections in the IPF patients.
RESULTS
RESULTS
In this systematic review and meta-analyses, 32 studies were selected based on the exclusion/inclusion criteria. Geographical distribution of included studies was: eight studies in American people, 8; in European people, 15 in Asians, and one in Africans. The pooled prevalence for viral and bacterial infections w ere 53.72% (95% CI 38.1-69.1%) and 31.21% (95% CI 19.9-43.7%), respectively. The highest and lowest prevalence of viral infections was HSV (77.7% 95% CI 38.48-99.32%), EBV (72.02%, 95% CI 44.65-90.79%) and Influenza A (7.3%, 95% CI 2.66-42.45%), respectively. Whereas the highest and lowest prevalence in bacterial infections were related to Streptococcus sp. (99.49%, 95% CI 96.44-99.9%) and Raoultella (1.2%, 95% CI 0.2-3.08%), respectively.
CONCLUSIONS
CONCLUSIONS
The results of this review were confirmed that the presence of viral and bacterial infections are the risk factors in the pathogenesis of IPF. In further analyses, which have never been shown in the previous studies, we revealed the geographic variations in the association strengths and emphasized other methodological parameters (e.g., detection method). Also, our study supports the hypothesis that respiratory infection could play a key role in the pathogenesis of IP.
Identifiants
pubmed: 33579274
doi: 10.1186/s12931-021-01650-x
pii: 10.1186/s12931-021-01650-x
pmc: PMC7880524
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Références
Am J Clin Pathol. 2003 Apr;119(4):556-67
pubmed: 12710128
Thorax. 2009 Aug;64(8):692-7
pubmed: 19359270
Mod Pathol. 2014 Jun;27(6):851-62
pubmed: 24232864
Am J Respir Crit Care Med. 2002 Aug 15;166(4):510-3
pubmed: 12186829
PLoS One. 2011;6(12):e27800
pubmed: 22205929
Respir Res. 2017 Feb 1;18(1):29
pubmed: 28143484
Thorax. 1996 Mar;51(3):315-7
pubmed: 8779139
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Lancet Respir Med. 2014 Jul;2(7):511-3
pubmed: 24767768
ERJ Open Res. 2020 Aug 17;6(3):
pubmed: 32832526
Clin Rev Allergy Immunol. 2011 Apr;40(2):117-34
pubmed: 20838937
Am Rev Respir Dis. 1992 Jul;146(1):266-8
pubmed: 1320820
J Clin Invest. 1988 Dec;82(6):2026-37
pubmed: 3264290
Infection. 2020 Feb;48(1):19-35
pubmed: 31482316
Eur Respir J. 2011 Feb;37(2):356-63
pubmed: 20595144
Ann Med. 2012 Mar;44(2):178-86
pubmed: 21254895
Eur Respir J. 1997 Sep;10(9):2040-5
pubmed: 9311499
Proc Am Thorac Soc. 2006 Jun;3(4):357-63
pubmed: 16738201
OMICS. 2010 Feb;14(1):9-59
pubmed: 20141328
Mediators Inflamm. 2019 Jan 3;2019:5160694
pubmed: 30718973
Eur Respir J. 2007 Nov;30(5):835-9
pubmed: 17978154
Chest. 2001 Jul;120(1 Suppl):74S-75S
pubmed: 11451937
Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L441-4
pubmed: 22180659
Eur Respir Rev. 2013 Sep 1;22(129):376-81
pubmed: 23997064
J Virol. 2005 Jun;79(11):6890-9
pubmed: 15890928
J Immunol. 1997 Jan 15;158(2):954-9
pubmed: 8993016
Stat Med. 2002 Sep 30;21(18):2641-52
pubmed: 12228882
Thorax. 2000 Nov;55(11):958-61
pubmed: 11050267
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
J Physiol Pharmacol. 2004 Sep;55 Suppl 3:67-75
pubmed: 15611595
Am J Respir Crit Care Med. 2011 Jun 15;183(12):1698-702
pubmed: 21471095
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1336-41
pubmed: 10194186
Arch Pathol Lab Med. 2011 Jun;135(6):780-8
pubmed: 21631273
Eur Respir Rev. 2012 Dec 1;21(126):355-61
pubmed: 23204124
Psychol Methods. 2006 Jun;11(2):193-206
pubmed: 16784338
PLoS One. 2020 Apr 3;15(4):e0230746
pubmed: 32243456
Antioxid Redox Signal. 2008 Feb;10(2):287-301
pubmed: 17961066
Chest. 2020 May;157(5):1175-1187
pubmed: 31730835
Am J Respir Crit Care Med. 2014 Oct 15;190(8):906-13
pubmed: 25184687
Front Med (Lausanne). 2018 Mar 20;5:43
pubmed: 29616220
Respirology. 2008 Mar;13(2):263-9
pubmed: 18339026
Respir Med. 2001 Oct;95(10):787-91
pubmed: 11601742
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
PLoS One. 2013;8(2):e55715
pubmed: 23468849
J Med Microbiol. 2017 Nov;66(11):1602-1606
pubmed: 29068280
Respirology. 2005 Sep;10(4):504-9
pubmed: 16135175
Iran J Pathol. 2020 Winter;15(1):30-33
pubmed: 32095147
Respir Med. 2018 Mar;136:88-92
pubmed: 29501253
J Clin Microbiol. 2003 Jun;41(6):2633-40
pubmed: 12791891
Clin Respir J. 2018 May;12(5):1787-1801
pubmed: 29316311
PLoS One. 2010 Jan 05;5(1):e8578
pubmed: 20052417
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S186-92
pubmed: 26595738
Braz J Med Biol Res. 2013 Nov 18;46(11):985-992
pubmed: 24270907
Stat Med. 2010 Dec 20;29(29):3046-67
pubmed: 20827667
J Glob Infect Dis. 2017 Apr-Jun;9(2):66-72
pubmed: 28584458
Eur Respir J. 1997 Jul;10(7):1445-9
pubmed: 9230228
PLoS One. 2009 Oct 23;4(10):e7559
pubmed: 19851501
Respir Investig. 2014 Jan;52(1):65-70
pubmed: 24388373
Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1119-26
pubmed: 18390830
Intern Med. 2015;54(9):1015-9
pubmed: 25948340
Microb Pathog. 2017 Dec;113:190-196
pubmed: 29038056